iECURE
iecure.com
Cell & Gene Therapy
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Knocking down devastation. Inserting hope. At iECURE, we believe in vivo gene editing is the answer to meeting this immense patient need, and we believe reversing the course of these conditions is now within reach.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Decreased rate of hyperammonemiccrises in infants with neonatal-onset OTC deficiency (OTCD) post ECUR-506 administration
https://iecure.com/wp-content/uploads/2026-SSIEM-Platform-Final-Baruteau-aug27.pdfThe post Decreased rate of hyperammonemiccrises in infants with neonatal-onset OTC deficiency (OTCD) post ECUR-506 administration first appeared on iECURE.
Read more
Report
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026
#top .av-special-heading.av-mt0kk247-c0aff6cb70e7cef96d678d8b77329a5e{ padding-bottom:50px; } body .av-special-heading.av-mt0kk247-c0aff6cb70e7cef96d678d8b77329a5e .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-mt0kk247-c0
Read more
Report
iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
PHILADELPHIA, August 20, 2026--iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM
Read more
Report
iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
#top .av-special-heading.av-mt0kk247-377ee4edaaffb5647a5f6f11a13c150c{ padding-bottom:50px; } body .av-special-heading.av-mt0kk247-377ee4edaaffb5647a5f6f11a13c150c .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-mt0kk247-37
Read more
Report
Social Media Community Guidelines
Our social media channels are intended to share information about iECURE, genetic medicine, clinical research, rare disease education, and the communities we serve.
Read more
Report
Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: Preliminary update from the OTC-HOPE study
https://iecure.com/wp-content/uploads/Ecure_Garrod_Poster_Website.pdfThe post Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: Preliminary update from the OTC-HOPE study first appeared on
Read more
Report
iECURE named one of the 2026 Best Places to Work by the Philadelphia Business Journal for the third year in a row.
Read more
Report
Sustained Clinical Response in First Patient Dosed With ECUR-506 One Year Post Discontinuation of Standard of Care
https://iecure.com/wp-content/uploads/Ecure_SIMD_Poster_42x42.pdfThe post Sustained Clinical Response in First Patient Dosed With ECUR-506 One Year Post Discontinuation of Standard of Care first appeared on iECURE.
Read more
Report
iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial
#top .av-special-heading.av-mp7h4v2g-4d8826c49b2b2998f03b38d7f35f3579{ padding-bottom:50px; } body .av-special-heading.av-mp7h4v2g-4d8826c49b2b2998f03b38d7f35f3579 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-mp7h4v2g-4d
Read more
Report
Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: preliminary update from the OTC-HOPE study
https://iecure.com/wp-content/uploads/ASGCT-2026_iECURE_Presentation.pdfThe post Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: preliminary update from the OTC-HOPE study first appeared
Read more
Report
Show more news